

Sixth District Department of Correctional Services POLICY	Issue Date 10/13/17	Effective Date 09/09/22	Policy Number 175-22
SUBJECT OPIOID OVERDOSE INTERVENTION NARCAN (NALOXONE)		Review Month September	Author 0601 (GSC)
Rescinds 175-21	References Iowa Code: 147.76, 135.190		

POLICY:

In the event of a suspected opioid overdose or exposure, staff monitor clients, visitors, or other 6th Judicial District Department of Correctional Services (DCS) staff for signs of an opioid overdose or exposure and are prepared to respond by activating the EMS system, performing Cardio-Pulmonary Resuscitation (CPR) if certified, rescue breathing when deemed appropriate, and administering Narcan (Naloxone) Nasal Spray.

PURPOSE:

To describe the procedures utilized by the District in recognizing an opioid overdose or exposure, the proper procedures for the use of Naloxone during an opioid overdose or exposure, as well as procedures for maintaining Naloxone in a safe and secure environment.

DEFINITION:

1. Respiratory Distress - Slow breathing, less than one (1) breath every five (5) seconds or no breathing at all;
2. Unresponsiveness - No response to verbal commands or painful stimulus and not alert. Individual may have a slow, erratic, or lack of a pulse;
3. Naloxone - A prescription medication indicated for reversal of opioid-related drug overdose or exposure.
4. Standing Order - The authorization, issued pursuant to Iowa Senate Files 2218 and House Files 2460, which permits an Iowa Pharmacy to distribute Naloxone to certain eligible recipients without a doctor's prescription written for a specific individual, when the pharmacist has complied with the rules of the Iowa Board of Pharmacy.

PROCEDURE:

1. The Iowa Department of Corrections (DOC), has established a procedure which permits the dispensing of Naloxone to individuals or facilities where an overdose or exposure may occur that is caused by an opioid drug. Narcan Nasal Spray was selected as the form of Naloxone to be kept and utilized in both DOC correctional facilities and CBC locations.
2. The District Director or designee is responsible for determining the quantity of Narcan Nasal Spray to be kept at each facility. The medication comes in a box containing two (2) sprays and is stored at room temperature in a secure location unopened and accessible to all authorized staff.

POLICY NUMBER 175-22
PAGE 2 OF 3

PROCEDURE: (continued)

3. Staff are responsible for reading the Iowa Department of Public Health informational pamphlet "Opioid Overdose Recognition and Response" that is provided with the Narcan Nasal Spray as part of the training and education which is required by the Iowa Board of Pharmacy as a condition of the medication's dispensing. The directions for the ready-to-use nasal spray are found within the pamphlet as well as contained in the package of Narcan.
4. All staff also receives specific training as required by the Iowa Board of Pharmacy.
 - A. All staff (including new hires) must receive an instructor led training in person or via real time webinar- to clarify the procedure of Naloxone use, and to provide the opportunity for questions.
 - B. Training includes information on:
 - 1) Signs and symptoms of an overdose or exposure;
 - 2) Steps to be taken when an opioid overdose or exposure is suspected;
 - 3) How to use the Narcan;
 - 4) Necessary documentation
 - 5) How to obtain Narcan supplies.
 - C. Once the training has been completed, the designated staff member may then use the appropriate Narcan supply.
 - D. After the initial training a yearly training review is required of all staff to be done via E-Learning.
5. An individual experiencing an opioid overdose or exposure may display the following symptoms:
 - A. Pale face;
 - B. Clammy skin;
 - C. Pinpoint pupils;
 - D. Cyanosis (blue) around the lips and finger nails;
 - E. Slow respiration rate, Agonal (abnormal) breathing, or no breathing;
 - F. Unresponsiveness.

POLICY NUMBER 175-22

PAGE 3 OF 3

PROCEDURE: (continued)

6. If an opioid overdose or exposure is suspected, the following steps are taken:
 - A. Activate the Emergency Medical Service (EMS) System/Call 911;
 - B. Check for scene safety and utilize personal protective gear if available (ex. gloves, mask, protective glasses);
 - C. Check for responsiveness of the patient by tapping them on the shoulders and shouting "Are you ok?"
 - D. Check for a pulse and respirations;
 - E. If patient is absent of pulse and respiration, begin CPR if certified, utilizing AED if necessary;
 - F. If patient has a pulse but is not breathing, begin rescue breathing;
 - G. Administer one dose of Narcan Nasal Spray according to the package directions: one (1) spray in ONE (1) nostril
 - H. Continue CPR or Rescue Breathing until EMS arrives.
 - I. If patient does not respond in two (2) to three (3) minutes, a second dose of Narcan can be administered in the opposite nostril; doses can be repeated every two (2) to three (3) minutes until EMS arrives or patient responds
7. Following the administration of Narcan, patients who have been taking opioids may be disoriented, uncomfortable, or combative; opioid withdrawal symptoms can be unpleasant. Patients may need comfort. In addition, the Narcan effects subside anywhere from thirty (30) minutes to two (2) hours of the patient's overdose, and the overdose effects can return. It is crucial the patient receive medical attention immediately, and be transported to a hospital.
8. On-call Supervisor or staff's Supervisor is notified immediately of the incident.
9. Any use of Narcan Nasal Spray results in the creation of a Critical Incident Report (S002). All incidents are documented in a written report and/or in ICON and reviewed by the District Director or designee.
10. The District Director or designee ensures that all unused Narcan (Naloxone) in the District is replaced prior to its expiration date. Replenishment of Narcan Nasal Spray may be done by contacting the DOC Central Pharmacy, 420 Mill Street SW, Mitchellville, IA 50169, (515)-725-5065. The dispensing of the medication includes a signed receipt from staff receiving the supply, as required by the Iowa Board of Pharmacy.

BY ORDER OF:

Bruce Vander Sanden, District Director